<DOC>
	<DOCNO>NCT00002215</DOCNO>
	<brief_summary>To compare proportion patient whose plasma HIV-1 RNA level fall remain limit quantification Roche Amplicor Monitor ( 400 copies/ml ) [ AS PER AMENDMENT 8/4/98 : 50 copies/ml ] week 0 24 . To determine short-term safety tolerability MKC-442 plus nelfinavir ( Viracept ) plus dual nucleoside analog . To determine time viral failure time tolerability failure Week 48 therapy .</brief_summary>
	<brief_title>A Randomized , Double-Blind Study MKC-442 Combined With Viracept Patients Who Are Epivir + Retrovir Experienced Are Protease Inhibitor- Non-Nucleoside Reverse Transcriptase Inhibitor-Naive</brief_title>
	<detailed_description>In randomize , placebo-controlled study , patient allow switch entry d4T plus 3TC d4T plus ddI base investigator patient preference . Patients stratify base number nucleoside reverse transcriptase inhibitor ( NRTI ) treatment change entry screen HIV-1 RNA ( obtain within 30 day entry ) follow : switch 1 NRTI 10,000-50,000 copies/ml v switch 1 NRTI great 50,000 copies/ml v switch 2 NRTIs 10,000-50,000 copies/ml v switch 2 NRTIs great 50,000 copies/ml . Patients randomize within stratum 1 follow treatment arm : Arm 1 : MKC-442 placebo plus nelfinavir . Arm 2 : MKC-442 plus nelfinavir . Arm 3 : MKC-442 plus nelfinavir ( high dose ) . Treatment administer 48 week . Patients consider virologic success Week 48 may continue receive MKC-442 discretion investigator .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emivirine</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : At least 1 different nucleoside analog , e.g. , 3TC , d4T , ddI ( exclude zidovudine ) . Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia . Short course ( less 21 day ) acyclovir acute treatment . Recombinant erythropoietin GCSF Grade 3 great anemia neutropenia , respectively . Allowed caution close patient monitoring : Ketoconazole , fluconazole , itraconazole , grapefruit juice . Medications metabolize cytochrome P450 . Oral contraceptive , contraceptive implant Norplant , injectiontype contraceptive DepoProvera sole method contraception . Patients may : HIV1 RNA great 10,000 . No active AIDSdefining illness . Prior experience 2 nucleoside analogue able switch least 1 different nonnucleoside analog , e.g. , lamivudine ( 3TC ) , stavudine ( d4T ) , didanosine ( ddI ) HIV1 RNA 10,000 copies/ml less . [ AS PER : 8/4/98 AMENDMENT ] . [ AS PER AMENDMENT 8/4/98 : Nucleoside analognaive patient must HIV1 RNA great 50,000 copies/ml. ] . Prior Medication : Allowed : Treatment 2 nucleoside analog . Note : able switch least 1 different nucleoside analog e.g. , lamivudine ( 3TC ) , stavudine ( d4T ) , didanosine ( ddI ) , study [ AS PER AMENDMENT 8/4/98 ] . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active AIDSdefining illness . Malabsorption syndrome severe chronic diarrhea within 30 day entry , inability consume adequate oral intake due chronic nausea , emesis , abdominal esophageal discomfort . [ AS PER AMENDMENT 8/4/98 ] . Inadequately controlled seizure disorder [ AS PER AMENDMENT 8/4/98 ] . Any intercurrent illness could affect viral load determination [ AS PER AMENDMENT 8/4/98 ] . Concurrent Medication : Excluded : Zidovudine . Immunomodulators ( e.g. , systemic corticosteroid , interleukin2 , interferon ) . [ AS PER AMENDMENT 8/4/98 ] . Rifampin , rifabutin , phenobarbital , hydantoin . Amiodarone , quinidine , astemizole , terfenadine , ergot derivative , midazolam , triazolam , cisapride . Neurotoxic agent ( e.g. , vincristine , thalidomide ) . [ AS PER AMENDMENT 8/4/98 ] . Patients follow prior condition exclude : History acute chronic pancreatitis . History &gt; grade 2 peripheral neuropathy . Patients acute clinically significant medical event within 30 day screen . Prior Medication : Excluded : Protease inhibitor . Nonnucleoside reverse transcriptase inhibitor . Excluded within 30 day study drug administration : Immunomodulators ( e.g. , systemic corticosteroid , interleukin2 , interferon ) . [ AS PER AMENDMENT 8/4/98 ] . Rifampin , rifabutin , phenobarbital , hydantoin . Amiodarone , quinidine , astemizole , terfenadine , ergot derivative , midazolam , triazolam , cisapride . Immunotherapeutic vaccine . Cytotoxic chemotherapeutic agent [ AS PER AMENDMENT 8/4/98 ] . Prior Treatment : Excluded within 30 day study drug administration : Radiation therapy [ AS PER AMENDMENT 8/4/98 ] . Risk Behavior : Excluded : Current alcohol illicit drug use , opinion investigator , may interfere ability patient comply dose schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Uracil</keyword>
</DOC>